MiR-582-3p alleviates osteoarthritis progression by targeting YAP1

被引:25
作者
He, Jun [1 ]
Su, Xiaotao [1 ]
Xie, Wenwei [2 ]
机构
[1] Univ South China, Affiliated Nanhua Hosp, Dept Spine Surg, Hengyang 421001, Hunan, Peoples R China
[2] Dongguan Songshan Lake Cent Hosp, Dept Orthoped, Dongguan 523326, Guangdong, Peoples R China
关键词
miR-582-3p; YAP1; Osteoarthritis; CHONDROCYTE DIFFERENTIATION; PATHWAY; KNEE; MANAGEMENT; REGULATORS; EXPRESSION; MICRORNAS; CARTILAGE; PAIN;
D O I
10.1016/j.molimm.2020.10.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Osteoarthritis (OA) is a widespread degenerative joint disease that affects more than 350 million people worldwide. Although YAP1 has been proved to play a key role in OA, the biological function and mechanism of YAP1 in OA still need further investigation. In the present study, we demonstrated that YAP1 was highly expressed in OA rat chondrocytes. Recently, growing microRNAs (miRNAs) have been reported to play important roles in OA development. Among them, miR-582-3p is one of the few significantly downregulated miRNAs and attracted our attention. Functional investigations indicated that miR-582-3p inhibited chondrocyte apoptosis, reduced the proinflammatory cytokine production and suppressed extracellular matrix (ECM) degradation. Subsequently, molecular mechanism exploration implied that YAP1 is a downstream target of miR-582-3p. Furthermore, rescue assays revealed that YAP1 amplification can reverse miR-582-3p mimic-mediated effects on chondrocyte apoptosis, inflammatory response, and ECM degradation. Moreover, the OA rat model was established to explore the function of miR-582-3p/YAP1 axis in vivo. The results showed that YAP1 overexpression can recover the effects induced by injection of AAV-miR-582-3p mimic on OA progression. To sum up, these findings implied a crucial role of miR-582-3p/YAP1 axis in OA, which may provide a promising therapeutic strategy for OA.
引用
收藏
页码:258 / 267
页数:10
相关论文
共 31 条
[1]   MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease [J].
Baby, Nimmi ;
Alagappan, Nithyakalyani ;
Dheen, Shaikali Thameem ;
Sajikumar, Sreedharan .
AGING CELL, 2020, 19 (01)
[2]   Autophagy Is a Protective Mechanism in Normal Cartilage, and Its Aging-Related Loss Is Linked With Cell Death and Osteoarthritis [J].
Carames, Beatriz ;
Taniguchi, Noboru ;
Otsuki, Shuhei ;
Blanco, Francisco J. ;
Lotz, Martin .
ARTHRITIS AND RHEUMATISM, 2010, 62 (03) :791-801
[3]   A bioinformatic analysis of microRNAs role in osteoarthritis [J].
Cong, L. ;
Zhu, Y. ;
Tu, G. .
OSTEOARTHRITIS AND CARTILAGE, 2017, 25 (08) :1362-1371
[4]   Yap1 Regulates Multiple Steps of Chondrocyte Differentiation during Skeletal Development and Bone Repair [J].
Deng, Yujie ;
Wu, Ailing ;
Li, Pikshan ;
Li, Gang ;
Qin, Ling ;
Song, Hai ;
Mak, Kinglun Kingston .
CELL REPORTS, 2016, 14 (09) :2224-2237
[5]   Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes [J].
Diaz-Prado, Silvia ;
Cicione, Claudia ;
Muinos-Lopez, Emma ;
Hermida-Gomez, Tamara ;
Oreiro, Natividad ;
Fernandez-Lopez, Carlos ;
Blanco, Francisco J. .
BMC MUSCULOSKELETAL DISORDERS, 2012, 13
[6]  
Gu HJ, 2019, AM J TRANSL RES, V11, P2940
[7]   Reciprocal Feedback Loop of the MALAT1-MicroRNA-194-YAP1 Pathway Regulates Progression of Acute Pancreatitis [J].
Gu, Lina ;
Liu, Jingyao ;
Xu, Dan ;
Lu, Ying .
MEDICAL SCIENCE MONITOR, 2019, 25 :6894-6904
[8]   YAP1 is required for the angiogenesis in retinal microvascular endothelial cells via the inhibition of MALAT1-mediated miR-200b-3p in high glucose-induced diabetic retinopathy [J].
Han, Ning ;
Tian, Wen ;
Yu, Na ;
Yu, Li .
JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (02) :1309-1320
[9]   Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis [J].
Hayami, T ;
Pickarski, M ;
Zhuo, Y ;
Wesolowski, GA ;
Rodan, GA ;
Duong, LT .
BONE, 2006, 38 (02) :234-243
[10]  
Hu Guoku, 2018, Oncotarget, V9, P18648, DOI 10.18632/oncotarget.24307